Payment overview · 2025
General Payments
$945.93
38 reported records · 15 companies
Healthcare provider profile · identity verified
Carmen Josefa Perez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KINGWOOD, TX · NPI 1811950140
Verified facts
What the public records show
CMS Open Payments records show Carmen Josefa Perez, MD received $945.93 in general payments during 2025 across 38 reported records.
Novo Nordisk Inc accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $226.33 | 23.9% | 12 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $145.59 | 15.4% | 4 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $142.22 | 15.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.95 | 7.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.97 | 6.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.77 | 6.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.69 | 5.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$36.28 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.65 | 3.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.99 | 3.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.76 | 2.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.16 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.03 | 2.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.21 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.33 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $945.93 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $145.59 | 4 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $142.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $90.94 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $62.59 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.97 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.77 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $57.77 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $57.77 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.60 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $36.28 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 507 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 107 |
| Lisinopril | Lisinopril | 274 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 92 |
| Metformin Hcl | Metformin Hcl | 246 | 100 |
| Losartan Potassium | Losartan Potassium | 181 | 71 |
| Gabapentin | Gabapentin | 162 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 66 |
| Alprazolam | Alprazolam | 139 | 34 |
| Tramadol Hcl | Tramadol Hcl | 138 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 54 |
| Omeprazole | Omeprazole | 134 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 30 |
| Alendronate Sodium | Alendronate Sodium | 110 | 49 |
| Montelukast Sodium | Montelukast Sodium | 105 | 45 |
| Simvastatin | Simvastatin | 103 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 45 |
| Farxiga | Dapagliflozin Propanediol | 95 | 23 |
| Ozempic | Semaglutide | 93 | 30 |
| Ezetimibe | Ezetimibe | 91 | 37 |
| Carvedilol | Carvedilol | 89 | 29 |
| Cephalexin | Cephalexin | 89 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 30 |
| Famotidine | Famotidine | 75 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 31 |
| Clonazepam | Clonazepam | 66 | 15 |
| Nifedipine Er | Nifedipine | 64 | 19 |
| Sertraline Hcl | Sertraline Hcl | 64 | 27 |
| Trazodone Hcl | Trazodone Hcl | 64 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 23 |
| Temazepam | Temazepam | 59 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 18 |
| Lorazepam | Lorazepam | 52 | 14 |
| Metformin Hcl Er | Metformin Hcl | 52 | 21 |
| Glimepiride | Glimepiride | 51 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 23 |
| Furosemide | Furosemide | 49 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 22 |
| Meloxicam | Meloxicam | 47 | 20 |
| Nystatin | Nystatin | 47 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 20 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 14 |
| Allopurinol | Allopurinol | 35 | 12 |
| Glipizide | Glipizide | 35 | 15 |
| Potassium Chloride | Potassium Chloride | 35 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 11 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | 14 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Jardiance | Empagliflozin | 29 | 12 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | 13 |
| Cefuroxime | Cefuroxime Axetil | 25 | 23 |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 12 |
| Eliquis | Apixaban | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Spironolactone | Spironolactone | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 11 |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valtrex | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $945.93 · 38 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, Attruby, BREZTRI, COMIRNATY, Cologuard Collection Kit, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, PREVNAR 20, SHINGRIX, SYMPLICITY G3, TRELEGY ELLIPTA, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error